Cite
HARVARD Citation
Feemster, K. et al. (2022). Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert review of vaccines. pp. 589-590. [Online].